Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28788197 | 0.79 | KMT2A (0.37) | GPR119KMT2AMEN1HPGDBCHE | |
| SCHEMBL7421479 | 0.79 | GABRG2 (0.40) | KMT2AMEN1HPGDBCHENPC1 | |
| SCHEMBL26621269 | 0.75 | MLYCD (0.42) | MLYCD | |
| SCHEMBL28155365 | 0.75 | BCHE (0.37) | GPR119KMT2AMEN1HPGDNR1H2 | |
| SCHEMBL5268457 | 0.74 | OPRM1 (0.48) | MLYCDKMT2AMEN1HPGDNPC1 | |
| SCHEMBL19384688 | 0.74 | GPR119 (0.34) | GPR119MLYCDNR1H2USP30 | |
| SCHEMBL18068142 | 0.73 | BCHE (0.36) | GPR119NR1H2BCHEF2 | |
| SCHEMBL30798637 | 0.72 | MLYCD (0.36) | MLYCD | |
| SCHEMBL2959354 | 0.72 | BCHE (0.38) | GPR119KMT2AMEN1BCHEMAPT | |
| SCHEMBL2013279 | 0.72 | NOS1 (0.46) | GPR119KMT2AMEN1HPGDBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945796-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| CN-116438171-A | Substituted pyridine derivatives as SARM1 inhibitors | 努拉生物公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945796-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | GPR119 3596/4885MLYCD 2695/4885KMT2A 1817/4885 |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | GPR119 3596/4885MLYCD 2695/4885KMT2A 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.